Showing results (81-90 of 150) with videos related to
Sort By:
Pageof 15
International Journal of Radiation Oncology, Biology, Physics|July 4, 2025
Health-Related Quality of Life in Patients Treated for Nonmetastatic Muscle-Invasive Bladder Cancer: Radical Cystectomy Versus Bladder-Preserving TherapyKatharina Brück, Vera Atema, Annemarie M Leliveld, et al.European Urology|May 20, 2025
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 TrialMatthew D Galsky, Michiel S van der Heijden, Thomas Powles, et al.Future Oncology (London, England)|September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerRobert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.Frontiers in Immunology|January 6, 2022
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial CancerNick van Dijk, Alberto Gil-Jimenez, Karina Silina, et al.Science (New York, N.Y.)|May 25, 2004
Mutational analysis of the tyrosine phosphatome in colorectal cancersZhenghe Wang, Dong Shen, D Williams Parsons, et al.International Journal of Clinical Oncology|January 21, 2026
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinomaEiji Kikuchi, Michiel S Van der Heijden, Begoña P Valderrama, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trialT B Powles, M S Van der Heijden, Y Loriot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 StudySiamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.The Lancet. Oncology|May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialEvan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II TrialHielke M de Vries, Tynisha S Rafael, Alberto Gil-Jimenez, et al.Pageof 15